Dr Reddy’s Laboratories is trading higher by 2% at Rs 2,635 after drug maker said that it has launched generic version of Pfizer's Caduet tablets, a cholesterol-lowering drug, in US market.
The company has launched Amlodipine Besylate and Atorvastatin Calcium Tablets, a therapeutic equivalent generic version of Caduet (amlodipine besylate and atorvastatin calcium) tablets, in the US market, following the approval by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.
According to IMS Health sales data, Caduet tablets brand and generics had US sales of around $163 million for the most recent twelve months ending in January 2014.
The stock opened at Rs 2,600 and touched a high of Rs 2,637 on the BSE. A combined 106,000 shares changed hands on the counter so far on the BSE and NSE.
The company has launched Amlodipine Besylate and Atorvastatin Calcium Tablets, a therapeutic equivalent generic version of Caduet (amlodipine besylate and atorvastatin calcium) tablets, in the US market, following the approval by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.
According to IMS Health sales data, Caduet tablets brand and generics had US sales of around $163 million for the most recent twelve months ending in January 2014.
The stock opened at Rs 2,600 and touched a high of Rs 2,637 on the BSE. A combined 106,000 shares changed hands on the counter so far on the BSE and NSE.
